Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAB-001
- Development stage
- Discontinued
- Lead developer
- Promius Pharma, LLC
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
NAB-001 is a small molecule drug that was developed by Promius Pharma for the topical treatment of mild to moderate distal subungual onychomycosis (a fungal infection of the toenails). It was investigated in Phase 3 clinical trials as a topical therapy for this indication. The drug reached Phase 3 development but its global highest R&D status is now listed as discontinued. There are no publicly available details regarding its precise mechanism of action or molecular target[2][4]. Some sources mention "NAB 001" as a monoclonal antibody for Ebola virus disease[3], but all evidence from clinical trial registries and pharmaceutical databases indicates that the NAB-001 relevant to human trials and discontinued development is the small molecule antifungal agent from Promius Pharma.
- Other names
- ciclopirox nail lacquer
02
Targets
CaSR (Extracellular calcium-sensing receptor)
Beyond the preview
Go deeper on NAB-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAB-001.